These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38003469)

  • 21. Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series.
    Aledo-Serrano Á; Cabal-Paz B; Gardella E; Gómez-Porro P; Martínez-Múgica O; Beltrán-Corbellini A; Toledano R; García-Morales I; Gil-Nagel A
    Epilepsia Open; 2022 Sep; 7(3):525-531. PubMed ID: 35802036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A survey of seizures and current treatments in 15q duplication syndrome.
    Conant KD; Finucane B; Cleary N; Martin A; Muss C; Delany M; Murphy EK; Rabe O; Luchsinger K; Spence SJ; Schanen C; Devinsky O; Cook EH; LaSalle J; Reiter LT; Thibert RL
    Epilepsia; 2014 Mar; 55(3):396-402. PubMed ID: 24502430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
    Sullivan J; Simmons R
    Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Selective 5-HT
    Silenieks LB; Carroll NK; Van Niekerk A; Van Niekerk E; Taylor C; Upton N; Higgins GA
    ACS Chem Neurosci; 2019 Jul; 10(7):3284-3295. PubMed ID: 31082204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
    Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
    Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.
    Martin P; Reeder T; Sourbron J; de Witte PAM; Gammaitoni AR; Galer BS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
    Balagura G; Cacciatore M; Grasso EA; Striano P; Verrotti A
    CNS Drugs; 2020 Oct; 34(10):1001-1007. PubMed ID: 32875491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical spectrum of
    Wolking S; May P; Mei D; Møller RS; Balestrini S; Helbig KL; Altuzarra CD; Chatron N; Kaiwar C; Stöhr K; Widdess-Walsh P; Mendelsohn BA; Numis A; Cilio MR; Van Paesschen W; Svendsen LL; Oates S; Hughes E; Goyal S; Brown K; Sifuentes Saenz M; Dorn T; Muhle H; Pagnamenta AT; Vavoulis DV; Knight SJL; Taylor JC; Canevini MP; Darra F; Gavrilova RH; Powis Z; Tang S; Marquetand J; Armstrong M; McHale D; Klee EW; Kluger GJ; Lowenstein DH; Weckhuysen S; Pal DK; Helbig I; Guerrini R; Thomas RH; Rees MI; Lesca G; Sisodiya SM; Weber YG; Lal D; Marini C; Lerche H; Schubert J
    Neurology; 2019 Mar; 92(11):e1238-e1249. PubMed ID: 30737342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systems medicine strategy to predict the efficacy of drugs for monogenic epilepsies.
    Taweel B; Marson AG; Mirza N
    Epilepsia; 2022 Dec; 63(12):3125-3133. PubMed ID: 36196775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects].
    Nieto Barrera M; Candau Fernandez Mensaque R; Nieto Jiménez M
    Rev Neurol; 2003 Jul 1-15; 37(1):64-8. PubMed ID: 12861512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure to use new breakthrough treatments for epilepsy.
    Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
    Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research advances in basic mechanisms of seizures and antiepileptic drug action.
    Lasoń W; Chlebicka M; Rejdak K
    Pharmacol Rep; 2013; 65(4):787-801. PubMed ID: 24145073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of epilepsy: newly approved and developmental agents.
    Stephen LJ; Brodie MJ
    CNS Drugs; 2011 Feb; 25(2):89-107. PubMed ID: 21254787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monogenic idiopathic epilepsies.
    Gourfinkel-An I; Baulac S; Nabbout R; Ruberg M; Baulac M; Brice A; LeGuern E
    Lancet Neurol; 2004 Apr; 3(4):209-18. PubMed ID: 15039033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with brivaracetam in children - The experience of a pediatric epilepsy center.
    Nissenkorn A; Tzadok M; Bar-Yosef O; Ben-Zeev B
    Epilepsy Behav; 2019 Dec; 101(Pt A):106541. PubMed ID: 31698260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.